EN | RU
EN | RU

Help Support

Back

Upadacitinib improves patient-reported outcomes in rheumatoid arthritis

Upadacitinib improves patient-reported outcomes in rheumatoid arthritis Upadacitinib improves patient-reported outcomes in rheumatoid arthritis
Upadacitinib improves patient-reported outcomes in rheumatoid arthritis Upadacitinib improves patient-reported outcomes in rheumatoid arthritis

What's new?

Upadacitinib monotherapy found to be a good option for the management of rheumatoid arthritis patients as it effectively improves patient-reported outcomes.

Among methotrexate-naive and methotrexate-inadequate response individuals with active rheumatoid arthritis, upadacitinib monotherapy (at 15 or 30 mg) for 12/14 weeks led to remarkable improvements in pain, health-related quality of life (HRQOL), morning stiffness, work productivity and activity impairment (WPAI), and physical function in comparison with methotrexate alone.

A study was performed to investigate the effect of upadacitinib (a selective Janus kinase 1 inhibitor) monotherapy compared to methotrexate on patient-reported outcomes in moderate-to-severe active rheumatoid arthritis patients who were methotrexate-naive (n=945) or who had an inadequate response to methotrexate (n=648).

The patient-reported outcomes from the SELECT-EARLY and SELECT-MONOTHERAPY trials were assessed at Weeks 2 and 12/14. Included subjects were 18 years of age with rheumatoid arthritis symptoms for six weeks (SELECT-EARLY, methotrexate-naive) or diagnosed rheumatoid arthritis for three months (SELECT-MONOTHERAPY, methotrexate-inadequate response) and received upadacitinib monotherapy (15 or 30 mg) or methotrexate.

The patient-reported outcomes included the following: (i) Patient Global Assessment of Disease Activity (PtGA), (ii) Morning stiffness duration/severity, (iii) Health assessment questionnaire Disability Index (HAQ-DI), (iv) Pain visual analogue scale, (v) HRQOL by the 36-item Short Form Health Survey and WPAI (SELECT-EARLY), and (vi) Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (SELECT-EARLY).

The least square mean alterations and percentage of subjects witnessing improvements higher than or similar to the minimum clinically important differences (MCID) and normative values were assessed. In methotrexate-naive and inadequate response subjects, upadacitinib monotherapy (15 mg, 30 mg) compared to methotrexate led to greater reported  least square mean alteration from baseline at weeks 12/14 in HAQ-DI, PtGA, pain, FACIT-F (SELECT-EARLY), HRQOL, WPAI (SELECT-EARLY), and morning stiffness duration/severity

These alterations were clinically significant with both doses of upadacitinib compared to methotrexate at Weeks 12/14 in both the randomized control trials. Substantial improvements were noted in week 2. In comparison with methotrexate recipients, more upadacitinib-treated methotrexate-naive and inadequate response patients witnessed improvements higher than or comparable to the MCID and scores higher than or similar to the normative values.

Thus, upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis and offers an effective second-line therapy choice for rheumatoid arthritis subjects who have an unsatisfactory response to  methotrexate.

Source:

Rheumatology

Article:

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

Authors:

Vibeke Strand et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: